{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-101342","form_type":"8-K","ticker":"RZLT","cik":"0001509261","company_name":"Rezolute, Inc.","filed_at":"2024-09-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.308483+00:00","generated_at":"2026-05-31T03:36:05.845507+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Rezolute reports Q4 FY2024 net loss of $23M; FDA lifts partial clinical hold on ersodetug","bullets":["Q4 net loss $23.0M vs $12.7M prior year; full year net loss $68.5M vs $51.8M.","Cash and investments $127.1M at June 30, 2024, up from $118.4M year-over-year.","FDA lifts partial clinical holds on ersodetug for congenital HI; U.S. enrollment in Phase 3 sunRIZE expected early 2025.","Phase 3 study for tumor HI to begin H1 2025; topline results expected mid-2026.","Phase 2 RZ402 for DME met primary endpoints; partnering discussions ongoing."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-101342","json":"https://secwatch.observer/filing/0001104659-24-101342.json","markdown":"https://secwatch.observer/filing/0001104659-24-101342.md","text":"https://secwatch.observer/filing/0001104659-24-101342.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1509261/000110465924101342/0001104659-24-101342-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1509261/000110465924101342/tm2424269d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T03:36:05.845507+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}